A whole spectrum of neurological disorder studies was represented in the AAN, 21-27 April 2017, Boston. This newsletter compiles a number of studies related to risk-factor identification, clinical trials, pivotal clinical trial extension, real world data, innovative therapeutic approaches, presented in this meeting. The effect of intensive reduction of systolic blood pressure (BP) on hematoma expansion after intra-cerebral haemorrhage (ICH), were discussed. The identification of BP as the most important risk factor contributing to stroke and dementia, the potential ineffectiveness of cholinesterase inhibitors in mild cognitive impairment, the new guidelines on Sudden Unexpected Death in Epilepsy, the cannabidiol use for epilepsy, were presented. Immune therapies in migraine, the use of extended-release carbidopa-levodopa, subcutaneous apomorphine, and gene therapy in PD, were also presented. MS – related studies were impressively many. Among them, the use of autologous EBV-specific T-cells in PPMS, the con-current use of opicinumab and (IFN) beta-1a, im, in active RRMS or SPMS, the robust effects siponimod in SPMS, the use of dimethyl fumarate (DMF) in paediatric MS, data from the extension studies of Alemtuzumab, the rapid effect of ocrelizumab and the efficacy of cladribine tablets, were among the most spectacular news at the meeting.
Best Regards,
Professor Nikolaos Grigoriadis
Posted on
Previous Article
« Letter from the Editor Next Article
Interview with Prof. Matthias Heringlake »
« Letter from the Editor Next Article
Interview with Prof. Matthias Heringlake »
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com